Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, Tolerability and Pharmacokinetics of TWP-101 in Advanced Melanoma and Urothelial Carcinoma
NCT04871334Phase 1Unknown
- Sponsor
- Therawisdom Biopharma
- Start
- Feb 2021
- Primary completion
- Oct 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of sytalizumab in melanoma and urothelial carcinoma (UC) (2 cohorts), sponsored by Therawisdom Biopharma. Primary endpoints: Incidence of Dose-Limiting Toxicity at 4 weeks and Incidence of Adverse Events, Serious Adverse Events, and Immune-Related Adverse Events. Status: unknown.
02
Drugs
sytalizumab
03
Conditions
melanomaurothelial carcinoma (UC)
Beyond the preview
Go deeper on NCT04871334.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04871334.